Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ASCO 2018 Results of the TAILORx trial

Joseph Sparano, oncologist at Montefiore Medical Center, explains the results of the TAILORx trial, which he presented during the plenary session at ASCO 2018. This trial attempted to incorporate a gene expression test into clinic decision making for hormone receptor positive breast cancer.

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 27/06/2018

ASCO 2018 Rechallenge with bevacizumab in ovarian cancer

Dr. Sandro Pignata, oncologist and president of the Multicentre Italian Trial in Ovarian cancer (MITO) group, explains the results of the MITO 16b trial. This study evaluated whether the addition of bevacizumab to a platinum-based chemotherapy prolongs survival for recurrent ovarian cancer patients who had already received it during first line.

Meet the author 22/03/2018

E-learning: Quarterly Focus on Breast Cancer

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, has developed a new program format, the 'Quarterly Focus', which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. Two pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Gabe Sonke, MD, Ph.D, medical oncologist, NKI-AVL Amsterdam, Netherlands Ester Siemerink, MD, Ph.D, medical oncologist, Ziekenhuis Groep Twente, Hengelo/Almelo, Netherlands Rianne Oosterkamp, MD, medical oncologist, Haaglanden Medisch Centrum, Den Haag, Netherlands Invited speakers: Prof. George Sledge, MD, medical oncologist Stanford University School of Medicine, California, US MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy J Clin Oncol, 2017 Prof. Laura van 't Veer, molecular biologist UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades JAMA Oncol, 2017